PROQR THERAPEUTICS NV

$7.76 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About PROQR THERAPEUTICS NV

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Stock Analysis

last close $7.76
1-mo return 1.2%
3-mo return 41.6%
avg daily vol. 606.54T
52-week high 9.46
52-week low 3.4
market cap. $521M
forward pe -
annual div. -
roe -56.6%
ltg forecast -
dividend yield -
annual rev. $2M
inst own. 68.5%
baraka

Subscribe now for daily local and international financial news

Subscribe